Susan F. Slovin, MD, PhD, discusses selecting among available treatment options for patients with metastatic castration-sensitive prostate cancer.
Susan F. Slovin, MD, PhD, medical oncologist, associate vice chair, Academic Administration, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses selecting among available treatment options for patients with metastatic castration-sensitive prostate cancer (mCSPC).
Many drugs can be used in the treatment algorithm for mCSPC, but the standard of care continues to be androgen deprivation therapy with either docetaxel, enzalutamide (Xtandi), apalutamide (Erleada), or abiraterone acetate (Zytiga), according to Slovin. Additionally, darolutamide (Nubeqa) could potentially be added to this treatment, Slovin explains.
Selecting one approach over another requires a discussion about toxicities, interactions with other drugs, and the potential benefit that will be derived for the patient, Slovin adds. Patients who are more symptomatic may benefit more from a combination with chemotherapy; however, all available agents have been FDA approved based on survival benefit and are feasible options, Slovin concludes.